Sernova Corp. (PSH.F)
| Previous Close | 0.2900 |
| Open | 0.2804 |
| Bid | 0.2886 x 1000000 |
| Ask | 0.3008 x 1000000 |
| Day's Range | 0.2598 - 0.3028 |
| 52 Week Range | 0.2588 - 0.7795 |
| Volume | |
| Avg. Volume | 5,538 |
| Market Cap | 91.872M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- News Direct
Sernova Provides Organizational Update
LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of reg...
- News Direct
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors
Dr. Daniel Mahony to step down to pursue new commitment
- GlobeNewswire
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hem
